Lupin is on track with timelines for new product launches and expects US Food and Drug Administration (FDA) approval for its generic version of Teva's ProAir (albuterol sulfate metered dose inhaler) in the first half of its fiscal 2021. The key asset is expected to help propel the Indian firm’s growth in the inhalation segment in the US, but approval timelines have been somewhat unclear thus far.
Lupin Awaits 'Clarity' On Albuterol Filing
Says Other US Launches On Track Despite Deferred FDA Inspections
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
More from Strategy
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
More from Business
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.